The earnings call highlighted significant progress in Sangamo's collaborations and clinical advancements, particularly with the Fabry program, alongside recognition at a major scientific meeting. However, it also underscored immediate financial challenges and dependence on securing a partnership for long-term sustainability.

Company Guidance -

Q3 2025

During the Sangamo Therapeutics First Quarter 2025 Teleconference Call, the company provided guidance on several key metrics and operational strategies. They announced a third capsid licensing agreement with Eli Lilly, which includes an $18 million upfront fee and potential for up to $1.4 billion in milestone payments. The neurology pipeline is advancing with preparations for a Phase 1/2 study of ST-503, targeting chronic neuropathic pain, with patient enrollment expected in mid-2025 and preliminary efficacy data by Q4 2026. The Fabry program achieved significant milestones with all 32 patients in the Phase 1/2 study having completed at least 52 weeks of follow-up, which is required by the FDA for accelerated approval. A pivotal data readout is anticipated by the end of this quarter, and a BLA submission is expected as early as Q1 2026. Financially, the company announced an equity offering to extend their cash runway to late Q3 2025, aiming to secure a commercial partnership for the Fabry program to support their neurology mission. The company reduced non-GAAP operating expenses by 50% year-on-year in 2024, emphasizing a lean operational model to achieve key milestones.

Collaboration with Eli Lilly for STAC-BBB

Sangamo Therapeutics signed a worldwide exclusive license agreement with Eli Lilly for the STAC-BBB capsid, potentially worth up to $1.4 billion in milestone payments and royalties. This is the third such agreement following partnerships with Genentech and Astellas.

Advancement in Fabry Program

Sangamo announced all patients in the Phase 1/2 STAAR study completed at least 52 weeks of follow-up, an FDA requirement for accelerated approval. Preliminary analysis showed positive mean eGFR slopes, and a pivotal data readout is expected by the end of the quarter.

Equity Financing to Extend Cash Runway

Sangamo announced an equity offering to extend their cash runway, which is expected to provide the necessary bridge to secure a commercial partnership for their Fabry program.

Recognition at ASGCT Annual Meeting

Sangamo was selected to present during the Presidential Symposium at the ASGCT Annual Meeting, highlighting their advancements in epigenetic regulation and capsid delivery technology.

Sangamo Biosciences (SGMO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SGMO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.09 / -	0.04	―	―	―
Aug 07, 2025	2025 (Q2)	-0.01 / -0.08	-0.18	55.56% (+0.10)
May 12, 2025	2025 (Q1)	-0.12 / -0.14	-0.27	48.15% (+0.13)
Mar 17, 2025	2024 (Q4)	-0.09 / -0.11	-0.34	67.65% (+0.23)
Nov 12, 2024	2024 (Q3)	-0.01 / 0.04	-0.59	106.78% (+0.63)
Aug 06, 2024	2024 (Q2)	-0.15 / -0.18	-0.66	72.73% (+0.48)
May 09, 2024	2024 (Q1)	-0.21 / -0.27	0.125	-316.00% (-0.40)
Mar 13, 2024	2023 (Q4)	-0.26 / -0.34	-0.32	-6.25% (-0.02)
Nov 01, 2023	2023 (Q3)	-0.32 / -0.59	-0.34	-73.53% (-0.25)
Aug 08, 2023	2023 (Q2)	-0.34 / -0.66	-0.29	-127.59% (-0.37)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SGMO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.48	―	―
May 12, 2025	$0.75	$0.46	-38.67%
Mar 17, 2025	$1.01	$0.85	-15.84%
Nov 12, 2024	$2.71	$2.44	-9.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sangamo Biosciences (SGMO) report earnings?

Sangamo Biosciences (SGMO) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Sangamo Biosciences (SGMO) earnings time?

Sangamo Biosciences (SGMO) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SGMO EPS forecast?

SGMO EPS forecast for the fiscal quarter 2025 (Q3) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing